Ponatinib (Iclusig®), under development by ARAID Pharmaceuticals, entered a Phase II trial in summer 2013 for patients with inoperable or metastatic GIST.   The three trial locations are Dana Farber Cancer Institute, Fox Chase Cancer Center and Oregon Health Science University.  This open-label trial will enroll about 30 patients with exon-11 GIST and about 15 patients with other GIST mutation types. 

Trial enrollment of new patients was halted by the FDA in October 2013 due to safety concerns about blood clots.

For more about ponatinib and teh halt of the trial see our website page.